Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brimonidine-Timolol Generic vs Combigan in Open Angle Glaucoma or Ocular Hypertension
2025-523227-22-00Phase 3Authorised
- Sponsor
- OmniVision
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of brimonidine tartrate + timolol maleate in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by OmniVision. Primary endpoint: Mean diurnal IOP change from baseline to week 12. Planned start Sep 2026; status: authorised.
02
Drugs
brimonidine tartrate + timolol maleate
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2025-523227-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523227-22-00.